Vontobel Holding Ltd. lessened its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 6.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,556 shares of the specialty pharmaceutical company’s stock after selling 291 shares during the quarter. Vontobel Holding Ltd.’s holdings in Jazz Pharmaceuticals were worth $560,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in the stock. Daiwa Securities Group Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 2.5% in the 3rd quarter. Daiwa Securities Group Inc. now owns 4,076 shares of the specialty pharmaceutical company’s stock valued at $528,000 after purchasing an additional 100 shares during the last quarter. Prime Capital Investment Advisors LLC lifted its holdings in shares of Jazz Pharmaceuticals by 4.3% during the 4th quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company’s stock valued at $325,000 after acquiring an additional 108 shares in the last quarter. Johnson Investment Counsel Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 0.8% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 13,096 shares of the specialty pharmaceutical company’s stock valued at $1,695,000 after acquiring an additional 110 shares in the last quarter. Fifth Third Bancorp lifted its holdings in Jazz Pharmaceuticals by 2.2% in the 3rd quarter. Fifth Third Bancorp now owns 5,339 shares of the specialty pharmaceutical company’s stock worth $691,000 after buying an additional 114 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its holdings in Jazz Pharmaceuticals by 5.6% in the 3rd quarter. CIBC Asset Management Inc now owns 2,264 shares of the specialty pharmaceutical company’s stock worth $293,000 after buying an additional 121 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.
Insider Buying and Selling at Jazz Pharmaceuticals
In related news, CFO Philip L. Johnson acquired 12,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were purchased at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the purchase, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CFO Philip L. Johnson acquired 12,000 shares of the company’s stock in a transaction on Friday, March 1st. The shares were purchased at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the purchase, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. Company insiders own 4.40% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Analysis on JAZZ
Jazz Pharmaceuticals Stock Down 1.0 %
JAZZ stock opened at $108.83 on Tuesday. Jazz Pharmaceuticals plc has a 52-week low of $106.61 and a 52-week high of $146.70. The company’s 50 day simple moving average is $119.51 and its 200-day simple moving average is $122.28. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. The firm has a market capitalization of $6.86 billion, a P/E ratio of 17.78, a P/E/G ratio of 1.52 and a beta of 0.59.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. As a group, equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 EPS for the current year.
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Read More
- Five stocks we like better than Jazz Pharmaceuticals
- The How And Why of Investing in Oil Stocks
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- ETF Screener: Uses and Step-by-Step Guide
- Merger or Not, Albertson’s Companies is a Good Buy
- What is MarketRank™? How to Use it
- 3 Cheap Stocks That Shouldn’t Be So
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.